Abbott collaborates with Biocon’s subsidiary to open first nutrition R&D center

03 May 2012 Evaluate

Abbott, one of the India’s largest health care companies, have unveiled plans to establish its first nutrition research and development center in the country in collaboration with Syngene, India’s leading contract research organization and also subsidiary of Biocon.

The Abbott Nutrition R&D Center in India will focus on the development of science based, affordable nutrition products for the country and enable the expansion of Abbott’s nutrition product portfolio there. It will focus on development of nutrition products for maternal and child nutrition and diabetes care.

Abbott Selected the largest biotech company in India-Syngene, to provide a science based research and innovation team to work closely with Abbott researchers. More than 50 researchers and scientists will be based at Abbott Nutrition R&D Center in India at Biocon Park, which is expected to open in June 2012.

Biocon is Asia’s leading R&D based Biotechnology Company. It produces anti-diabetic agents like Acarbose, Pioglitazone, Repaglinides and Rosiglitazone. In the biological segment it produces Insulin, Erythropoietin (EPO), Filgrastim (GCSF), Streptokinase and Monoclonal Antibodies. The drug major also produces mycophenolate mofetil, sirolimus and tacrolimus.

Biocon Share Price

316.15 -4.65 (-1.45%)
31-Oct-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1849.05
Dr. Reddys Lab 1274.25
Cipla 1553.20
Lupin 2184.00
Zydus Lifesciences 1001.85
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.